drugset
drugset / Trial / NCT06253130

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

NCT06253130 ↗

Phase 1/2 Recruiting 156 enrolled Eikon Therapeutics Impact Therapeutics, Inc. · collab
NaSequentialOpen-labelTreatment

Summary

This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.

Timeline

Start
2023-12-11
Primary completion
2027-06-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject IMP1734 Unknown — Oral

Indications

neoplasm